D-0233-2024 Class I Ongoing
FDA drug recall D-0233-2024 was initiated by Pfizer Inc. on Dec 21, 2023 and is designated Class I. Reason for recall: Presence of Particulate Matter; identified as glass The recall status is ongoing. Affected quantity: 34000 Cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 24, 2024
- Initiation Date
- Dec 21, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 34000 Cartons
Product description
4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case).
Reason for recall
Presence of Particulate Matter; identified as glass
Distribution pattern
Nationwide in the USA and Puerto Rico.
Code information
Lot GX1542, Exp. 01/01/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0233-2024
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.